Findings

What do systematic reviews say?

110 questions · 112 findings · 67 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 52 · 46.4%GRADE not reported 2 · 1.8%Very low 9 · 8%Low 13 · 11.6%Moderate 19 · 17%High 17 · 15.2%

Glycerin/glycerol‐containing moisturisers vs vehicle or placebo

Change from baseline in health‐related quality of life ‐ not measured · people with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Emollients and moisturisers for eczema 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1164 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1541 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

NSAIDs vs placebo

Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Subacromial decompression vs Placebo (sham/placebo device)

Health status and quality of life · people with impingement syndrome without full‐thickness rotator cuff tears

1 finding from 1 review

Subacromial decompression surgery for rotator cuff disease 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 285 participants
High

Intranasal corticosteroids vs placebo

Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis

1 finding from 1 review

Intranasal corticosteroids for non‐allergic rhinitis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis

1 finding from 1 review

Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 214 participants
Moderate

Spinal cord stimulation vs placebo

QoL · adults with low back pain

1 finding from 1 review

Spinal cord stimulation for low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Moderate

Summary of findings ‐ Inhaled mannitol vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis

Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).

1 finding from 1 review

Inhaled hyperosmolar agents for bronchiectasis 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 840 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 766 participants
Moderate

Mepolizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1285 participants
Moderate